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Abstract
Background: Zinc (Zn) is an essential trace element and it is abundant in connective tissues, however biological roles of Zn
and its transporters in those tissues and cells remain unknown.
Methodology/Principal Findings: Here we report that mice deficient in Zn transporter Slc39a13/Zip13 show changes in
bone, teeth and connective tissue reminiscent of the clinical spectrum of human Ehlers-Danlos syndrome (EDS). The
Slc39a13 knockout (Slc39a13-KO) mice show defects in the maturation of osteoblasts, chondrocytes, odontoblasts, and
fibroblasts. In the corresponding tissues and cells, impairment in bone morphogenic protein (BMP) and TGF-b signaling
were observed. Homozygosity for a SLC39A13 loss of function mutation was detected in sibs affected by a unique variant of
EDS that recapitulates the phenotype observed in Slc39a13-KO mice.
Conclusions/Significance: Hence, our results reveal a crucial role of SLC39A13/ZIP13 in connective tissue development at
least in part due to its involvement in the BMP/TGF-b signaling pathways. The Slc39a13-KO mouse represents a novel animal
model linking zinc metabolism, BMP/TGF-b signaling and connective tissue dysfunction.
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Introduction
Zn is an essential trace element [1] and its homeostasis in the
single cell and in whole organisms is tightly controlled by two
major families of Zn transporters, Zn importers (SLC39s/ZIPs) [2]
and exporters (SLC30s/ZnTs) [3], and Zn-binding proteins
metallothioneins (MTs) [4]. Mice strains carrying mutations in
genes related to zinc metabolism show various defects of
development [5,6]. Children affected by the recessive condition
acrodermatitis enteropathica (AE) have low serum concentrations
of Zn because of mutations in the intestinal Zn transporter
SLC39A4/ZIP4. These patients suffer from severe skin disease
and frequent infections [7,8]. Zn is essential for the function of
molecules with domains such as Zn-finger, Ring-finger and LIM
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domains [9,10]. In addition, Zn has been implicated as signaling
molecule or as affecting intracellular signaling pathways [5]. A
nematode ZnT1 orthologue, CDF1, positively affects Ras-ERK
signal transduction [11]. Slc39a7/Zip7 was found to affect EGF/
IGF signaling and tamoxifen resistancy of breast cancer cells [12].
Slc39a6/Zip6/Liv1 controls the nuclear localization of the Zn-
finger transcription factor Snail [13]. Extracellular signals, such as
toll-like receptor 4 (TLR4)- and FceR1-mediated stimulation,
induce the change of intracellular level of free Zn in dendritic cells
and mast cells, respectively, and this in turn controls the biological
activities of extracellular stimuli [14,15]. These reports all support
the idea that Zn is an intracellular signaling molecule and lead to
the prediction that Zn transporters have roles not only for
maintaining Zn homeostasis, but also for mediating intracellular
signaling events [5].
In Zn-deficient conditions, bone growth retardation and
increase of skin fragility are commonly observed [16,17]. Indeed,
Zn concentrations are high in bone, cartilage, and teeth[18], and
Zn may play a role in bone metabolism by stimulating bone
formation and mineralization [19]. Zn is also condensed in
epidermal and dermal cells and in their extracellular matrix
(ECM) [20,21]. The MT-null mice show low concentration of Zn
in skin, and the epidermis fails to exhibit hyperplasia [22]. These
evidence suggests an important role of Zn in development of both
hard and soft connective tissues, which require well-coordinated
local paracrine regulators such as BMP and TGF-b to be
developed [23,24,25,26]. Human genetics studies revealed that
they play a pivotal role for connective tissue development [27,28].
The Ehlers-Danlos syndrome (EDS) is a group of genetic
disorders affecting connective tissues. Several types are distin-
guished based on clinical features, inheritance pattern, and
molecular basis [29]. Many of them originate from changes in
the primary structure or posttranslational modifications of fibrillar
collagens [30]. While our studies were in progress, a mutation in
SLC39A13 was found in two families with a newly recognized
variant of EDS [31], similar to the one we observed in two sibs (see
below). In that work, emphasis is given to the impairment in
collagen lysyl hydroxylation, a feature observed also in our
patients, but no explanation is given for the short stature and other
phenotypic features observed, which clearly distinguish the novel
EDS type from EDS VIA (procollagen lysyl hydroxylase
deficiency). Other EDS types, such as EDS type VIB or EDS
type VIID, and related conditions such as the Brittle Cornea
Syndrome [32] are still awaiting molecular elucidation; intrigu-
ingly, the causative gene for the Brittle Cornea Syndrome has been
found to be a Zn-finger gene [33].
Here we report that knockout of Slc39a13 in mice results in a
generalized skeletal and connective tissue disorder, and that a
homozygous loss of function mutation in SLC39A13 is found in a
unique type of the EDS in human subjects. In addition, Slc39a13
controls intracellular Zn distribution and is involved in BMP and
TGF-b signal transduction pathways in connective tissues. Thus,
our results allow to establish a genetic and functional link between
the Zn transporter Slc39a13 and connective tissue development,
showing the usefulness of the Slc39a13-KO mouse as a novel
animal model for human connective tissue diseases.
Results
Reduced osteogenesis and abnormal cartilage
development in Slc39a13-KO mice
To examine the physiologic role of Slc39a13 in vivo, we
performed gene depletion (Figures S1A and S1B). Slc39a13-KO
mice showed growth retardation (Figures 1A and S2) and
developed progressive kyphosis after 3 or 4 weeks of age
(Figure 1B). Slc39a13-KO mice showed several abnormalities in
bone: 1) Skull and long bones were radiolucent (Figure 1C, left and
middle); 2) Decrease in cortical bone thickness, number of
trabeculae, and bone volume (three-dimensional micro-computed
tomography (3D-mCT), Figure 1C, right); 3) Decrease in bone
mineral density (BMD) in skull, mandible, and cortex and
cancellous of femur (Figure S3A); 4) Reduction of bone volume/
total tissue volume (BV/TV) and osteoid thickness (O.Th) in tibial
metaphyses (Figure S3B); 5) Double-labeling analysis using calcein,
a marker of newly formed bone, revealed that calcification
activities such as mineral apposition ratio (MAR) and bone
formation rate (BFR/BS), an indicator of osteoblast function, were
decreased (Figure S3C). However, eroded surface (ES/BS), the
numbers of osteoclasts (N.Oc/B Pm), and osteoclast-covered bone
surface (Oc.S/BS) were essentially equivalent to those in wild-type
littermates (Figure S3D). These data indicated that Slc39a13-KO
mice had reduced osteoblast activity with little alteration of
osteoclast activity.
In addition to decrease of bone mass, Slc39a13-KO mice had a
significant reduction in long bone length (Figure S4A). The width
Figure 1. Growth retardation, kyphosis, osteopenia, and
abnormal cartilage development in Slc39a13-KO mice. A. 5-
week-old female wild-type and Slc39a13-KO mice. A bar indicates
10 cm. B. Kyphosis in Slc39a13-KO mouse. Appearance and radiographs
of 5-week-old mice. C. Osteopenia of Slc39a13-KO mice. X-rays of skull
(left), femur and tibia (middle) of 4-week-old mice. 3D-mCT of the tibial
diaphysis (right). D. Slc39a13-KO mice show elongated growth plate
with uncoordinated columnar formation, and decrease hypertrophic
zone. Tibia from 4-week-old Slc39a13-KO mice and wild-type littermates
stained with H&E. Large views of growth plate are shown in middle and
lower panels. PZ, proliferative zone; HZ, hypertrophic zone. E. Gene
expression of Col10a1 and Ihh gene are diminished in growth plate of 4-
week-old Slc39a13-KO mice. Bar indicates 300 mm. ISH images.
doi:10.1371/journal.pone.0003642.g001
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of growth plate was elongated (Figures 1D and S4C), where
hypertrophic chondrocytes were rarely observed; instead irregu-
larly organized proliferative chondrocytes were present (Figure 1D,
bottom right). These abnormalities were apparently observed after
2 or 3 weeks of age (Figure S4C). In Slc39a13-KO chondrocytes,
type 10 collagen RNA (Col10a1), a marker for hypertrophic
chondrocytes, was diminished (Figure 1E, upper). Expression level
of Fgfr3, Sox9, Sox5 and Sox6, all of them crucial for chondrocyte
differentiation, were altered in Slc39a13-KO chondrocytes (Figure
S4B, left). In addition, expression of Indian hedgehog (Ihh), a
marker for the pre-hypertrophic zone, was downregulated in
Slc39a13-KO cartilage (Figure 1E, lower). These results strongly
suggested that differentiation from proliferative to hypertrophic
chondrocytes was impaired in Slc39a13-KO mice. The microarray
data also revealed that expression of genes regulating cell adhesion
and polarity was diminished in Slc39a13-KO chondrocytes (Figure
S4B, right), suggesting a role of Slc39a13 in cellular organization
during chondrocytes differentiation.
Reduced dentin and alveolar bone, and abnormal
craniofacial features in Slc39a13-KO mice
Slc39a13-KO mice showed abnormal incisor teeth (Figure 2A):
malocclusion, deformity, and breakage (3D-mCT, Figure 2A,
lower). They showed reduced root dentine formation of molar
teeth and bone volume of both mandible and alveolar
(backscattered electron (BEN) image, Figure 2C upper; 3D m-
CT, Figure 2C lower; H&E, Figure 2D), with little morpholog-
ical change in teeth crowns of molar (Figure 2C, upper right).
These data indicated an indispensable role of Slc39a13 in the
proper development of root dentin, mandible, and alveolar
bones. We also noted some changes in the craniofacial
morphology of Slc39a13-KO mice. The eyes were sunken,
giving an enophthalmos-like appearance, and the palpebral
fissures were downslanting (Figure 2B). Measurements of maxilla
and mandible bones showed that both bones were remarkably
smaller in Slc39a13-KO than in wild-type mice (Figure S5).
These results indicated that Slc39a13 has a crucial role for teeth
and craniofacial development.
Decreased dermal and corneal stromal collagen in
Slc39a13-KO mice
In addition to hard tissue abnormalities, the strength of skin
under tension was significantly reduced (Figure 3B). In fact,
dermal collagen fibrils layer was obviously thinner in Slc39a13-
KO than in wild-type mice (Figure 3A, lower panels of left and
middle). Ultrastructual analysis by transmission-electron microg-
raphy (TEM) of dermal collagen fibrils in Slc39a13-KO mice
demonstrated significant decrease and wide variation in size
compared with those in wild-type mice (Figures 3D and 3E). At
the same time, the epidermis layer did not show significant
differences between Slc39a13-KO and wild-type mice (Figure 3A,
right; enlarged view of blue-box area 1), indicating that the
function of collagen-producing cells might be impaired in
Slc39a13-KO mice. In fact, morphology of Slc39a13-KO
fibroblasts was changed in dermis (Figure 3C, enlarged view of
green-box area 2 in Figure 3A); spindle-shaped and often stellate
with cytoplasmic extension in wild-type mice, they were mostly
round–shaped in Slc39a13-KO mice. In addition to dermis,
substantia propria (SP) was markedly thinner in Slc39a13-KO
eye, while corneal epithelial cell (CEP) layer was not affected
(Figures 3F and 3G). Therefore, Slc39a13 may participate in
skin and eye development by controlling dermal and corneal
stromal fibroblast functions.
Mutation of SLC39A13 in Ehlers-Danlos syndrome with
short stature and skeletal and connective tissue
anomalies
We studied a pair of sibs with short stature and skeletal and
connective tissue disease that could not be ascribed to any of the
known EDS types or other connective tissue disorders known so
far (Figures 4A–4F, and Case reports). We first observed reduced
urinary excretion of hydroxylated collagen metabolites, but
mutation analysis of several collagen 1 and 3 genes as well as
procollagen hydroxylase genes failed to show pathogenic muta-
tions (Case reports). Analysis of the SNP microarray data obtained
in the family members revealed a single larger region of complete
homozygosity pericentromeric to chromosome 11 (10 Mb encom-
passing 227 genes). Further screening of this region by microsat-
ellite mapping (Figure 4G) suggested that two parents shared
alleloidentical haplotypic blocks. The location of SLC39A13 within
the region of homozygosity in combination with the strong
Figure 2. Abnormal teeth and craniofacial development in
Slc39a13-KO mice. A. Slc39a13-KO mice develop abnormal incisor
teeth (upper). 5-week-old Slc39a13-KO mice show evidence of
malocclusion (red arrow head), deformity (blue arrow head), and
breakage (yellow arrow head) of incisor teeth. Lower panels show 3D
m-CT imaging analysis showing a systemic decrease in bone density
and abnormal tooth development of 5-week-old Slc39a13-KO mice
compared with wild-type littermates. B. Craniofacial features of
Slc39a13-KO mouse. Eye shows enophthalmos-like appearance and
downslanting palpebral fissures in Slc39a13-KO mouse. Representative
face images of 5-week-old wild-type and Slc39a13-KO mouse. C. Root
dentin formation of molar teeth (red arrow head) and the bone volume
fraction of mandible (yellow arrow head) are remarkably reduced in
Slc39a13-KO mice. BEN (upper) and 3D m-CT images (lower) of
mandibular molar regions in 5-week-old wild-type and Slc39a13-KO
mice are shown. D. Root dentin and alveolar bone are reduced in
Slc39a13-KO mice. Sagittal sections of mandibular molar regions in 5-
week-old wild-type and Slc39a13-KO mice were stained with H&E.
Boxed areas are reproduced at higher magnification. de: dentin, ab:
alveolar bone.
doi:10.1371/journal.pone.0003642.g002
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analogy between the clinical features in our patients and those
observed in the Slc39a13-KO mouse designated SLC39A13 as
candidate gene. Mutation analysis showed that both affected
individuals were homozygous, and the parents were heterozygous,
for a G to A transition at nucleotide c.221 (c.221G.A) predicting
the non-conservative amino acid substitution G74D (Figure 4H).
UniProt (Universal Protein Resource, http://www.uniprot.org)
describes the potential structural topology of SLC39A13/ZIP13 as
an eight-transmembrane protein as consistent with other family
members (Figure 4J) [34,35,36], and glycine 274 is located in the
second transmembrane domain of SLC39A13 and conserved
through all vertebrate species down to fish (Figures 4I and 4J, and
data not shown). Screening of 128 chromosomes of Caucasian
descent and an additional 48 chromosomes from Portuguese
descent did not reveal any instance of the c.221G.A mutation.
Thus, we inferred that c.221G.A/G74D was pathogenic, further
establishing the important role of SLC39A13 in connective tissue
development in mouse and human.
Figure 3. Decreased dermal and corneal stromal collagen in
Slc39a13-KO mice. A. Dermal collagen is decreased in Slc39a13-KO
mice. H&E staining shows 5-week-old Slc39a13-KO skin is thinner than
wild-type littermates (left), without significant difference in epidermis
(right; enlarged view of blue-boxed area 1). Azan staining shows
collagen fibril is decreased in Slc39a13-KO skin (middle). B. Fragility of
skin is increased in Slc39a13-KO mice. The strength of skin under
tension is weakened in 5-week-old Slc39a13-KO mice compared with
wild-type littermates (n = 3 for each). Data represent mean6S.D. C.
Magnified image of green-boxed area 2 in Figure 3A shows morphology
of dermal fibroblasts (red arrow) are spindle-shaped and often stellate
with cytoplasmic extension in wild-type, while they are mostly round to
oval in Slc39a13-KO mice. D. TEM images of transversely sectioned
dermal collagen from 5-week-old mice are shown. Bar; 500 nm. E.
Dermal collagen in 5-week-old Slc39a13-KO mice are characterized by
thinner in size (left), and lower density of collagen fibrils (right) than
that in a wild-type mice. Thirty-nine and 168 areas in TEM images of
wild-type and Slc39a13-KO samples, respectively were assessed. Data
represent mean6S.D. F. Collagen of corneal stroma is decreased in
Slc39a13-KO mice. H&E (left) and Azan (middle) staining show 5-week-
old Slc39a13-KO cornea is thinner than wild-type littermates. Magnified
images of red-boxed area in middle panel show the width of corneal
stroma (substantia propia; SP) is decreased in Slc39a13-KO cornea,
without significant difference in corneal epithelial cells (CEP) (right). G.
Relative ratio between SP versus CEP indicates significant reduction of
stromal collagen in Slc39a13-KO cornea compared with those of wild-
type (n = 5 for each). Data represent mean6S.D.
doi:10.1371/journal.pone.0003642.g003
Figure 4. Clinical features, and genetic and molecular evidence
of the SLC39A13mutation in the two subjects with short stature
and EDS. The elder affected sib is shown at age 22 with short stature
and with mildly shortened trunk (A), antimongoloid eye slant with lack
of periorbital tissue (B), missing upper lateral incisor tooth (C), thin and
finely wrinkled skin on the palm of his hands (D), severe varicosity of his
lower legs and feet (E), vertebral flattening with sclerosis of the
vertebral endplates (F, radiograph taken at age 18 years). G. Autozygous
haplotype blocks detected by SNP genotyping are represented by the
black boxes, while blocks detected by microsatellite analyses are
represented as solid boxes in different colors (the common ancestral
haplotype being represented in red). The microsatellites used are
shown on the left, and the numbers refer to microsatellites’ alleles.
Gene density (GD) for local transcripts is shown in the center. Individual
genes are depicted as small circles, shaded (for the olfactory receptor
genes clusters) or open (all other genes). The relative position of
SLC39A13 and of the centromere (CEN) are also indicated. H. Sequence
tracings from SLC39A13 amplicons showing homozygosity for a G to A
transition changing codon 74 from glycine to aspartic acid in the two
affected subjects (Pat-1 and Pat-2), as well as heterozygosity in the
parents. I. Alignment of amino acid sequences of SLC39A13 protein
showing high conservation of sequences and in particular of glycine-74
(red box). J. Assignment of transmembrane domains of SLC39A13
(shaded boxes) was taken from Uniprot (http://www.uniprot.org). The
substitution of glycine-74 with aspartic acid was predicted to cause a
six-residue shift of the second transmembrane domain towards the
carboxy end by HMMTOP program (http://www.enzim.hu/hmmtop/,
lower panel).
doi:10.1371/journal.pone.0003642.g004
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The Zn transporter Slc39a13 controls intracellular Zn
distribution
Taken together, all results obtained from Slc39a13-KO mice
and human cases indicated that Slc39a13 was required for
connective tissue development. Indeed, Slc39a13 gene was
relatively highly expressed in some tissues such as bone and eye
(Figure S1C). This gene was also expressed in osteoblasts of tibia
(Figures 5A1 and 5A2) and of alveolar bone (Figure 5C2), in
proliferative zone of growth plate (Figure 5B), and in odontoblasts
on the forming of the dentine of crown in molar tooth (Figure 5C1).
Fibroblasts in reticular layer of dermis of skin expressed Slc39a13
protein (Figure 5D). Collectively, Slc39a13 was expressed in cells
essential for connective tissue development.
Slc39a13 belongs to the SLC39/ZIP family of Zn transporters,
and therefore is expected to be located on the cell surface and/or
on the lumen of intracellular compartments [37], although neither
its cellular localization nor its function has been known previously.
We found that Slc39a13 protein was localized in perinuclear
region of osteoblasts, chondrocytes, pulpal cells, and of fibroblasts
(Figure 6A), and mainly located in Golgi apparatus (Figure 6B),
suggesting that Slc39a13 protein functions as an intracellular Zn
transporter in connective tissue forming cells. Consistent with this
hypothesis, while the overall Zn concentration in serum and in
dermal fibroblasts as a whole was similar in wild-type and in
Slc39a13-KO mice (data not shown), electron probe X-ray micro
analysis (EPMA) capable of detecting Zn level in a restricted area
of a single cell (Figure 6C, upper) [38] revealed that Zn level in
Golgi was increased in Slc39a13–KO primary dermal fibroblasts as
compared to that in wild-type cells (Figure 6C, lower right).
Considering the fact that members of the SLC39s/ZIPs family
function as transporters of Zn from the extracellular space into the
cytosol [37], all the evidence supports the notion that this
transporter Slc39a13 functions as a Zn transporter transporting
Zn from the Golgi to the cytosol and thus influences the Zn level at
least in areas of the cytosol, adjacent to the Golgi membrane. We
were unable to detect a significant change of the average Zn
concentration in the cytosol because apparently, the Zn concen-
tration detected by EPMA was very variable (data not shown);
cytosol space is broad and Zn content seems to be heterogeneous
from area to area in cytosol. We also found that the Zn
concentration in the cell nucleus was decreased in the absence
of Slc39a13 (Figure 6C, lower left), implicating that Slc39a13 also
affects the nuclear translocation of either Zn-binding proteins, or
Zn itself, or both. In their complexity, the results indicate that
Slc39a13 affects the intracellular distribution of Zn in connective
tissue forming cells.
Slc39a13 is involved in BMP/TGF-b signaling pathways in
connective tissue forming cells
To investigate further the consequences of genetic ablation of
Slc39a13, we explored molecular events taking place in Slc39a13-
KO mice by microarray analysis using primarily isolated
osteoblasts and chondrocytes. The pathway-Express program
[39] indicated that only BMP/TGF-b signaling was the cascade
that was commonly perturbed in both cell types by loss of Slc39a13
(P-value of hypergeometric distribution with Bonferroni type
multiple testing correction, ,0.01) (Figure S6A). Consistent with
this, we observed changes of gene expression in Scl39a13-KO
mice, such as depletion of Msx2, a homeobox gene crucially
involved in BMP-mediated bone and teeth development (Figures
S7 left and S8A), abnormal accumulation of Runx2, an essential
gene for osteoblast maturation (Figure S7, right), and decrease of
dermal type 1 collagen (Figure S8B). In addition, BMP4
stimulation in Slc39a13-KO primary osteoblasts failed to induce
Msx2 (Figure 7A), and Runx2 was instead overexpressed
(Figure 7A). Slc39a13-KO primary dermal fibroblasts showed
reduced induction of type 1 Collagen RNA (Col1a2) and Smad7 in
response to stimulation with TGF-b (Figure 7B). Ectopic
expression of Slc39a13 in Slc39a13-KO primary osteoblasts and
dermal fibroblasts recovered responsiveness against BMP4 and
TGF-b (Figures 7C, 7D and S10), establishing an essential role of
Slc39a13 for BMP4 and TGF-b signaling. Importantly, mouse
Slc39a13 carrying the homologous G to A substitution (G74D,
Figures 7C and 7D) as well as human SLC39A13 having the G to
A mutation obtained from EDS patients (data not shown) was
unable to fully rescue the unresponsiveness of osteoblasts and
fibroblasts isolated from Slc39a13-KO mice against BMP and
TGF-b, respectively, indicating that this mutation causes a loss of
function.
Smad transcription factors are major signal transducers of BMP
and TGF-b signaling [40,41]. They are phosphorylated by the
activated receptor complex, and subsequently translocate to the
nucleus to initiate transcription of their target genes. BMP4 and
TGF-b stimulation induced equivalent phosphorylation level of
Smad 1/5/8 (Smads) in Slc39a13-KO osteoblasts and Smad2
(Smad2) in Slc39a13-KO dermal fibroblasts, respectively (Figure
S6B). In contrast, nuclear localization of Smad proteins
(Figures 7E, 7F and S9C) as well as phosphorylated Smad proteins
(Figures S9A, S9B and S9D) was disrupted in BMP4 or TGF-b-
stimulated Slc39a13-KO cells. This was further confirmed by
immunoblotting utilizing subcellular fractions (Figures S9E and
S9F). These results suggested that Slc39a13 was involved in
nuclear localization of Smad proteins, but not for their
phosphorylation, in connective tissue forming cells.
Discussion
We herein described (1) that SLC39A13 is crucially involved in
connective tissue development, (2) the emerging role of the Zn
transporter SLC39A13 in BMP/TGF-b signaling in correspond-
ing tissues and cells, (3) that SLC39A13 dysfunction causes skeletal
and connective tissue disease both in mouse and man, (4) and thus
that Slc39a13-KO mouse is a novel animal model for human
connective tissue diseases.
Slc39a13-KO mice show osteopenia due to the reduction of
osteoblast activity (Figures 1C and S3). As shown in Figure 7, loss
of Slc39a13 caused dysregulation of BMP/TGF-b -mediated gene
expression including expression of Runx2 and Msx2, both of which
are critically involved in bone, tooth, and craniofacial skeletogen-
esis [42,43,44,45,46]. In BMP4-stimulated Slc39a13-KO osteo-
blasts, we observed simultaneous upregulation and depletion of
Runx2 and Msx2, respectively (Figure 7A). This pattern of
expression was also observed in vivo (Figure S7). Runx2 is essential
for osteoblast differentiation [42], meanwhile it represses func-
tional differentiation of osteoblasts when overexpressed in mice
[47], suggesting that proper control of its spatio-temporal
expression thus seems to be important for osteoblast differentiation
in vivo [48,49]. Msx2 is reported to promote osteoblast differen-
tiation independently of Runx2 [50]. Therefore, the Slc39a13 -
Msx2 gene expression axis may also be critical to lead appropriate
skeletal and craniofacial development. Slc39a13-KO mice show
evidence of impaired differentiation of chondrocytes in cartilage:
expression of Fgfr3 and Sox9 is dysregulated (Figure S4B, left), and
that of Ihh is disrupted (Figure 1E, lower). The gain-of-function
mutant of Fgfr3 causes achondroplasia [51], Sox9 controls
chondrocyte differentiation via Sox5 and Sox6 expression [52],
and Ihh is a master gene of bone development under BMP control
Role of ZIP13 in Development
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[53,54], suggesting that Slc39a13 exerts a profound influence on
genes crucial to chondrocyte differentiation. We also found
irregular formation of chondrocyte columns in Slc39a13-KO
growth plate (Figure 1D, bottom right), where expression of genes
required for tight junction and cellular polarity [55,56] were
diminished (Figure S4B, right). The irregularity in cellular
Figure 5. Cellular localization of Slc39a13. A. Slc39a13 gene is expressed in osteoblasts (1 and 2; red arrow head) in tibia of 4-week-old mice.
Regions indicated as 1 and 2 in top are magnified as 400 times. ISH images. B. Slc39a13 mRNA is expressed in proliferative zone of growth plate (left)
at 3-week-old tibia. Region indicated as 1 and 2 in top are enlarged at lower panels. PZ: proliferative zone. HZ: hypertrophic zone. C. Slc39a13 gene is
expressed in odontoblasts of 10-day-old molar teeth. ISH analysis shows Slc39a13 is expressed in odontoblast (black arrowhead) lining the dentin of
crown (1), and in osteoblast (red arrowhead) on the surface of alveolar bone (2). Regions indicated as 1 and 2 in top are magnified as 400 times. od:
odontoblasts, ab: alveolar bone. D. Slc39a13 protein expression in dermal fibroblasts. IHC analysis shows Slc39a13 protein is expressed in fibroblasts
in dermis of 5-week-old wild-type mice (left upper). Enlarged images of boxed areas are shown in IHC images. Bar indicates 10 mm.
doi:10.1371/journal.pone.0003642.g005
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morphology was also observed in Slc39a13-KO odontoblasts in the
molar tooth (Figure S8A, bottom left) and dermal fibroblasts
(Figure 3C); thus, Slc39a13 have a role in growth plate
architecture and cellular organization, implicating the possible
involvement of Slc39a13 in BMP/TGF-b signalings since they are
well recognized to control cell adhesion, polarity, and movement
[57], although we cannot exclude the possibility that other
signaling pathways are also affected by loss of Slc39a13. In teeth,
Slc39a13-KO mice show reduced normal formation of root dentin
in molar but no significant morphological changes in the molar
crown (Figure 2C, upper right), suggesting that teeth development
normally initiates without Slc39a13 and proceeds until bell stages.
From late bell stage, the epithelial and mesenchymal interactions
between ameloblasts and odontoblasts are activated, resulting in
mineralization, and the root of a tooth begins its development
once the crown formation has been established [58,59]. In
Slc39a13-KO mice, odontoblasts cannot sufficiently induce target
genes of BMP signaling such as Msx2 (Figure S8A), thus reduction
of the width of root dentin may occur since BMP has a crucial role
in this stage [60]. Intriguingly, the root was elongated normally in
Slc39a13-KO molar tooth (Figure 2C, upper right), suggesting that
Slc39a13 is required for root dentin accumulation but not for root
elongation. The skin of Slc39a13-KO mice was abnormally fragile,
most likely because of the reduction in dermal collagen fibrils
(Figures 3D and 3E). Similarly, corneal stromal collagen was
reduced in Slc39a13-KO eyes (Figures 3F and 3G). A functional
dysregulation of Slc39a13-KO fibroblasts (Figures 3C and 7B) is a
plausible reason why both skin and corneal development are
impaired in Slc39a13-KO mice, since fibroblasts and TGF-b are
required for their development and repair [26,61,62]. Slc39a13-
KO mice also showed lipoatrophy; the subcutaneous layer of
adipose tissue was significantly thinner in Slc39a13-KO than in
wild-type mice (Figure 3A, lower left), a finding present also in the
EDS patients (Case reports), suggesting that Slc39a13 may
determine the fate of other mesenchymal-originated cells like
Figure 6. Slc39a13 controls intracellular zinc distribution. A.
Slc39a13 protein locates on perinuclear region in primary osteoblasts
(1), chondrocytes (2), pulpal cells (3), and dermal fibroblasts (4).
Slc39a13, nuclei, and actin were stained with anti-Slc39a13 specific
antibody, DAPI, and phalloidin, respectively. Confocal microscopic
images. B. Slc39a13 is localized in Golgi. Confocal microscopic analysis
using dermal fibroblasts. Golgi, Slc39a13, nuclei, and actin is stained
with anti-GM130 antibody, anti-Slc39a13 specific antibody, DAPI, and
phalloidin, respectively. C. Upper: Schematic diagram of EPMA to detect
intracellular zinc level. Golgi and nucleus in primary dermal fibroblasts
are scanned by electron beam (EB), and characteristic X-ray (CX) for zinc
is detected. Lower: Slc39a13 involves in control of intracellular zinc
distribution. The ratio of zinc level in Golgi or nucleus versus total Zn in
those organelles (n = 11 and 10 for wild-type and Slc39a13-KO dermal
fibroblasts, respectively) was obtained by calculating counts per
seconds (cps) of CX for zinc generated by EB scanning; Zn level in
each organelle (%) = Each organelle Zn (cps)/{nuclear Zn (cps)+Golgi Zn
(cps)}6100. Data represents 6S.D.
doi:10.1371/journal.pone.0003642.g006
Figure 7. Slc39a13 is involved in BMP and TGF-b -mediated
signaling. A. Slc39a13 is involved in BMP4 -mediated gene expression.
Primary osteoblasts were stimulated with 50 ng/ml of BMP4 for
indicated periods, and gene expression including Slc39a13, Msx2,
Runx2, and Gapdh was examined by RT-PCR. B. Slc39a13 is involved in
TGF-b –mediated gene expression. Primary dermal fibroblasts were
incubated with 2.5 ng/ml of TGF-b1 for indicated periods, and gene
expression of Slc39a13, Col1a2, Smad7, and Gapdh was examined by RT-
PCR. C and D. Ectopic expression of mouse wild-type Slc39a13 (WT), but
not of G74D mutant (G74D), rescued BMP4 or TGF-b -induced gene
expression in Slc39a13-KO primary osteoblasts (C) or dermal fibroblast
(D), respectively, assessed by real-time PCR. Values represent
means6S.D. of three separate experiments. E and F. Slc39a13 is
involved in BMP/TGF-b –induced nuclear localization of Smad proteins.
Primary osteoblasts (E) or dermal fibroblasts (F) were stimulated with
either 50 ng/ml of BMP4 for 15 minutes (E, right panels) or 10 ng/ml of
TGF-b1 for 30 minutes (F, right panels), respectively, followed by
staining for Smad1, Smad2/3, nuclei (DAPI), and actin (Actin). Confocal
microscopic images.
doi:10.1371/journal.pone.0003642.g007
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adipocytes. It is also noteworthy that the physical strength of the
ocular bulbs in Slc39a13-KO mice was reduced (data not shown);
loss of Slc39a13 may be pathogenically linked to connective tissue
disorders associated with fragile eyes.
These mouse phenotypes of skeletal, dental, dermal, ocular, and
craniofacial changes were strongly reminiscent of human EDS and
OI [29,30,63,64,65,66]. We investigated a pair of sibs who had
short stature in combination with skeletal and connective tissue
changes that evoked EDS and OI. The SLC39A13 gene was
contained in a single region of homozygosity on chromosome 11,
and mutation analysis revealed a point mutation predicting the
substitution of a highly conserved amino acid (G74D) in the
second transmembrane domain (Figures 4I and 4J). A similar
substitution of the corresponding glycine (G330) to aspartic acid
(G330D) in the first transmembrane domain of SLC39A4/ZIP4
has been associated with the genetic disease, AE[8]. We showed
that the homologous mutation in SLC39A13 indeed causes loss of
function (Figures 7C and 7D). Accordingly, the individuals
homozygous for the SLC39A13 loss of function mutation were
affected by a disorder analogous to that observed in the Slc39a13-
KO mice and corresponding to the novel EDS variant. Indeed, the
recapitulation of the mouse phenotype by the human disorder is
extensive, and includes osteopenia, short stature, thin and fragile
skin, enophthalmos, thin sclerae, downslanting palpebral fissures
and dental anomalies. In agreement with our data, and while our
manuscript was being prepared, Giunta et al reported two families
with a SLC39A13 mutation and a novel type of EDS [31]. This
mutation they found was different from the one we identified but
was also predicted to cause loss of function. These authors focused
on the reduced excretion of hydroxylysine metabolites and suggest
inhibition of lysyl hydroxylase as the probable pathogenetic cause.
Indeed, we had also observed reduced urinary excretion of
hydroxylated collagen metabolites in our subjects. However, the
overall clinical picture of our patients and those described by
Giunta et al. is different from that of lysyl hydroxylase deficiency
(EDS VIA) with normal stature but severe muscular hypotonia
and marked looseness of skin and joints; thus, it is clear that the
pathogenetic mechanism postulated by Giunta et al., i.e., secondly
inhibition of procollagen lysyl hydroxylase activities, may be
operational but does not account for the short stature and the
additional features, including hypodontia, observed both in the
patients and in the mouse model. The defect in BMP/TGF-b
signaling that we have described is more consistent with the
phenotype; impaired TGF-b signaling fits well with short stature in
mouse and human, as increased TGF-b activity has been regarded
as the cause of tall stature in Marfan syndrome, another inherited
disorder of connective tissue [67,68]. Notably enough, some
clinical spectrum of the EDS patients and of Slc39a13-KO mice
actually resemble that of human cases and animal models of Zn-
deficiency, that show developmental abnormalities including
dwarfism, bone growth retardation, and increase of skin fragility
[16,17,22]. Thus, our combined findings in the mouse model and
in the human subjects are unequivocable and point to a ‘‘Zn -
connective tissues - BMP/TGF-b signaling’’ connection that
deserves thorough exploration.
Our data showed Slc39a13 is involved in BMP/TGF-b
signaling pathways in connective tissue forming cells and in
nuclear translocation of Smad proteins (Figures 7E, 7F, and S9).
Smad proteins are phosphorylated downstream of BMP or TGF-b
receptor complex, followed by nuclear translocation. Among the
Smad proteins, all receptor-regulated Smad (R- Smad) and Smad4
possess a Zn-binding motif in the MH1 domain for their DNA
binding [69]. At the moment, we do not know how Slc39a13
regulates the nuclear localization of Smad proteins, but our results
show that the Zn transporter Slc39a13 affects either directly or
indirectly BMP and TGF-b signaling pathways. Considering the
fact that there was no change of serum Zn concentration in both
cases of human patients (Case reports) and of Slc3913-KO mice
(data not shown) and that Slc39a13 is located in Golgi (Figure 6B),
it seems likely that Slc39a13 regulates the intracellular Zn
distribution. In fact, the Zn concentration at the whole-cell level
was unchanged, but the Zn level in the Golgi was increased in
Slc39a13-KO cells (Figure 6C, lower right), indicating that
Slc39a13 functions as a Zn transporter allowing for efflux of Zn
from the Golgi into the cytoplasm, where Zn is expected to
interact with Smad. Our data supported that Slc39a13 functions
as a Zn transporter controlling intracellular Zn distribution,
although we cannot exclude the possibility that Slc39a13 may
transport other metals, like Slc39a2/Zip2 for iron and calcium
[70], Slc39a14/Zip14 for iron [71], and Slc39a8/Zip8 for
cadmium [72]. At the moment it remains unknown how Zn is
transferred to its target molecule. It may be simplistic to assume
that Zn transporters such as Slc39a13 simply shuttle Zn ions across
the Golgi membrane, and that their effect is the result of changes
in the concentration of Zn in one or the other cell compartment.
Or, unknown ‘‘metal chaperone(s)’’ may transfer Zn directly from
a given Zn transporter to Zn binding molecule [73]. The
mechanisms how Slc39a13 regulates the nuclear localization of
Smad proteins should be an intriguing novel question, and the
demonstration of a complex perturbation of intracellular signaling
and of deregulation of gene expression in Slc39a13-ablated tissues
and cells indicates avenues for further research.
Taken together, the results obtained in Slc39a13-KO mice and
patients with EDS establish that the Zn transporter SLC39A13
controls intracellular Zn distribution and is involved in connective
tissue development. We showed SLC39A13 is required for full
activation of BMP and TGF-b signaling through controlling the
intracellular localization of Smad in connective tissue forming
cells. This would be at least one of the possible reasons why linear
growth, bone mineralization, root dentin formation, and fibro-
blastic collagen synthesis are impaired in Slc39a13-KO mice and
the EDS patients. The Slc39a13-KO phenotype, however, seems
to differ from typical BMP/TGF-b related-KO mice which show
more severe phenotypes than Slc39a13-KO mice [74]. This could
be explained in the following ways: 1) In Slc39a13-KO, BMP/
TGF-b signaling is affected only in those tissues where Slc39a13 is
expressed and functions non-redundantly. 2) In BMP or TGF-b
related-KO mice, all tissues are defective of their signaling. 3) In
Slc39a13-KO mice, in addition to BMP/TGF-b signaling, other
signaling pathways might be affected; all of these issues should be
unfolded in the future. Our study yields new insights into the
relevance of Zn transporters in the biological events, and illustrates
their role in health and disease. Thus, further exploration of the
role(s) of Zn transporters and of their dysfunction will reveal the
role(s) of Zn as a signaling molecule, shed light on other genetic
disorders of connective tissue, and help to understand the
pathophysiology of Zn-deficiency.
Materials and Methods
Generation of Slc39a13 -KO mice
Generation of knockout mouse line of the Slc39a13 gene was
performed using previously described methods [75]. A bacterial
artificial chromosome (BAC) clone containing the mouse Slc39a13
was screened from an embryonic stem (ES) cell–BAC library [76].
A targeting vector was created to eliminate the genomic region
encompassing exons 6–8 by inserting a Neo-cassette into a region
between exons 5 and 9 of Slc39a13 and deleting the intervening
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exons (Figure S1A). This region contains the conserved HEX-
PHEXGD motif common to SLC39/ZIP family members [2].
This vector was introduced into R1 ES cells and cloned
homologous recombinants were selected with antibiotics and the
genotypes verified. We developed chimeric mice with the targeted
ES cell clones and obtained homozygous mice by interbreeding
the offspring. Heterozygous mice were phenotypically normal, and
crosses between heterozygotes produced homozygous mutant mice
according to Mendelian expectations. All procedures including
mouse handling were conducted according to guidelines approved
by the RIKEN Institutional Animal Care and Use Committee.
Genotyping was done by PCR using LA taq (TAKARA BIO Inc.)
(Figure S1B). Primers used for genotyping are;
F; 59-CTTGTAGCCCACCAATCAGAGACCGATGAT-39
R1; 59-TGGTGGTCAGAAGCCCGATCT-39
R2; 59-GCTGCTAAAGCGCATGCTCCAGACTGCCTT-39
X-ray analysis of bones and teeth, and bone
histomorphometry
Radiographs, BMD, measurement of long bone length, and 3D-
mCT scans of bone were taken using a composite X-ray analyzing
system (In vivo 3D Micro X-ray CT System R_mCT, Rigaku).
The dissected mandibles were scanned using micro CT (MCT-100
MFZ, HITACHI). BEN was scanned using Electron Probe X-ray
Micro Analyzer (JXA9200 II, JOEL). Bone histomorphometric
analysis was performed by using the left tibia from 4-week-old
mice (n = 5) injected with calcein (Wako Pure Chemical Industries,
Ltd.) for in vivo fluorescent labeling (16 mg/kg body weight/10 ml)
at 1 and 4 days before sacrifice. The tibia was fixed in 70%
ethanol, and the undercalcified bone were embedded in
Glycolmetacrylate. 3-micrometer-thick section was cut longitudi-
nally in the proximal region of the tibia, and stained for toluidine-
blue-O and tartrate-resistant acid phosphatase (TRAP). Histo-
morphometry was performed with the semiautomatic image
analyzing system (Osteoplan II; Carl Zeiss) linked to a light
microscope. The histomorphometric measurements were made at
400 times using a minimum of 17,20 optical fields in the
secondary spongiosa area from the growth plate-metaphyseal
junction. Nomenclature, symbols, and units used are those
recommended by the Nomenclature Committee of the American
Society for Bone and Mineral Research [77].
Skeletal and teeth histology
Paraffin sections (4,6 mm) processed from tibia of 1, 2, 3 and 4-
week-old mice, mandible of 5-week-old mice, and molar tooth of
10 day-old mice were prepared for H&E staining, and for in situ
hybridization (ISH). Digoxigenin-labeled antisense RNA probes
for Slc39a13, Msx2, Runx2, Col10a1, and Ihh were used for ISH by
the method of GENOSTAFF Inc. The sections used in ISH
analysis were counterstained with Kernechtrot stain solution.
Probe sequences and hybridization conditions are available upon
request.
Skin and eye histomorphometry
Skin and eye isolated from 5-week-old mice were formalin-fixed
and paraffin-embedded. Paraffin sections (4 mm) were cut and
stained with H&E and Azan for histological analysis, and also used
for immuno histochemistry (IHC). We made a rabbit polyclonal
antibody specific to a peptide corresponding to the CLAQ-
PAAEPGLRAVVRNL sequence of mouse Slc39a13, which was
used for IHC (Figure 5D) and for confocal microscopic analysis
(Figure 6). We confirmed that this antibody was able to detect and
was specific to Slc39a13 since it did not show positive signals in
Slc39a13-KO cells, as shown in Figure 5D. For collagen type I
staining, anti-rabbit polyclonal antibody against collagen I
(Abcam) was used. To measure the fragility of skin, dorsal skin
of 5-week-old mice were chopped in 263 cm2, and the strength of
skin under tension was measured by a spring scale. For
transmission electron microscopy, skin biopsy samples were taken
from dorsal skin of 5-week-old wild-type and Slc39a13-KO mice,
and prepared as previously described [78]. For measurement of
collagen fibril density, the superficial dermis was photographed in
the central portion, and diameters were measured along the minor
axis of cross-sections using Image-Pro Plus (Media Cybernetics).
Quantitation of fibrils/nm2 was also measured from transmission
electron micrographs of cross-sections from dermis of the dorsal
skin region of mice using Image-Pro Plus (Media Cybernetics).
Confocal microscopy and immunoblotting
Cells cultured on glass coverslips in 35-mm Glass base dishes
(Iwaki) were stimulated and then fixed with 4% paraformaldehyde
in PBS. Immunostaining was done after cells were made
permeable with BD Perm/Wash Buffer containing antibodies
and 1% BSA. Fluorescence was detected with an inverted spectral
Confocal Scanning system TCS SP2 AOBS (Leica) with an oil
immersion 636 objective. Images were processed with Adobe
Photoshop Version 7.0. GM130 antibody (clone35, BD Trans-
duction Laboratories), DAPI (Molecular Probes), and Alexa
FluorH546 phalloidin (Molecular Probes) were used to visualize
Golgi, nuclei, and actin, respectively. Alexa FluorH 568 F(ab’)2
fragment of goat anti-mouse IgG (Molecular Probes), Alexa FluorH
488 F(ab’)2 fragment of goat anti-rabbit IgG (Molecular Probes)
were used for secondary staining. The following antibodies were
used for confocal microscopy and immunoblotting; anti-Smad1
(Zymed), anti-Smad2/3 (BD Transduction Laboratories), anti-
phosphorylated Smad1/5/8 (Cell Signaling), and anti-phosphor-
ylated Smad2 (Cell Signaling). Anti-tubulin (B-5-1-2, Sigma), anti-
Flag (Sigma), anti-HDAC1 (Sigma). We made a rabbit antibody
by immunization with a peptide corresponding to the NSKEDPS-
QAPSKDPTAA sequence of mouse Slc39a13, which was used for
immunoblotting (Figure S6). As shown in Figure S6B, this
antibody reacted with a 40 kDa molecule in wild type cells but
not in Slc39a13-KO cells. BMP4 and TGF-b1 were purchased
from R&D systems.
Subcellular fractionation
Cells were stimulated with BMP4 or TGF-b1 for indicated
periods, and then were lysed with hypotonic buffer (20 mM
HEPES pH 7.9, 0.1 mM EDTA, 0.2% NP-40, 10 mM NaCl,
1 mM DTT) supplemented with proteinase inhibitors for 5 min.
After centrifugation at 10,0006g for 1 min, cytoplasmic fraction
was isolated as supernatant. Precipitates were then incubated with
extraction buffer (20 mM HEPES pH 7.9, 0.1 mM EDTA, 0.2%
NP-40, 420 mM NaCl, 1 mM DTT) supplemented with protein-
ase inhibitors at 4uC for 30 min. Nuclear fraction was subse-
quently extracted by centrifugation (10,0006g, 4uC, 10 min). For
total cell lysates, cells were suspended with lysis buffer (1% NP-40,
20 mM Tris-HCl pH 7.4, 150 mM NaCl) supplemented with
proteinase inhibitors, and lysates were cleared by centrifugation
(10,0006g, 4uC, 10 min). 20 mg of each fraction were subjected to
SDS-PAGE, followed by immunoblotting.
Measurement of zinc distribution in cell
Electron Probe X-ray Micro Analyzer (JXA9200 II, JOEL)
assessed intracellular zinc distribution in primary dermal fibro-
blasts. Wild-type and Slc39a13-KO dermal fibroblasts were
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cultured in 6 well plates, and cells were fixed with 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer and post-fixed
in 1% osmium tetroxide. Subsequently, the cells were dehydrated
in an ascending series of alcohol and embedded in epoxy resin.
Electron beam scanned Golgi and nucleus of embedded cells.
Characteristic X-ray for zinc generated by electron beam exposure
was detected.
Gene expression profiles
Gene expression profiling was conducted using total RNAs
obtained from primary osteoblasts and chondrocytes of wild-type
and Slc39a13-KO mice. Biotinylated cRNA was synthesized using
a One-Cycle Target Labeling kit (Affymetrix) according to the
manufacturer’s manual and hybridized with Mouse Genome 430
2.0 Arrays (Affymetrix). The signal intensities for each probe set
were calculated using a gcRMA method in a Genespring GX 7.3
software package (Agilent). Using lists of genes exhibiting 2-fold
changes between wild-type and Slc39a13-KO cells, pathway
analysis was conducted on a Pathway Express program (http://
vortex.cs.wayne.edu/projects.htm#pathways-Express). The raw
data for microarray analysis are available from the Gene
Expression Omnibus (GEO) of the National Center for Biotech-
nology Information (NCBI; series accession nos. GSE10555 and
GSE10556). For RT-PCR analysis, total RNA was extracted from
cells and several tissues of C57/B6J mice using Sepasol-RNA I
(Nacalai tesque), and reverse-transcribed with oligo-(dT) primer
and a reverse transcriptase (ReverTra Ace, TOYOBO). SYBR
Green PCR Master Mix (Applied Biosystems) was used for real-
time PCR analysis. Primer sequences for RT-PCR and real-time
PCR are listed in Supplemental Tables S2 and S3, respectively.
Statistics analysis
Differences among multiple groups were compared by 1-way
ANOVA followed by a post-hoc comparison using Fisher’s PLSD
test. The two-tailed Student’s test was used to analyze difference
between 2 groups.
Human studies
The committee approved the studies and confirmed that
informed consent was obtained from human subjects as follows:
The patients were not recruited in a prospective study, but came to
us with a request for diagnostic help and genetic counseling owing
to our reputation as medical experts in skeletal and connective
tissue diseases. We have seen them at the Lausanne University
Hospital. Thus, our relationship with them falls under the
physician-patient relationship as defined by Swiss law; every single
procedure (clinical examination, venipuncture, radiography and
skin biopsy) is directly related to the diagnostic procedure and is
not per se a research procedure. Equally, analysis of the patients’
biologic material (urine, blood, DNA, cell culture) is part of the
routine diagnostic procedure to confirm or rule our known genetic
entities (in our case, the known forms of Ehlers-Danlos
syndromes). Although written consent is required only for surgical
operation with anaesthesia, which was not performed in our case,
we obtained both oral and written informed consent. The IRB has
granted approval for the informed consent for research procedures
of this type (i.e., non-surgical) to all activities performed within the
Swiss National Foundation research project ‘‘Molecular Bases of
Human Chondrodysplasias’’ (PIs: A. Superti-Furga and L.
Bonafe´). This is to cover for the performance of additional
procedures such as the sequencing of ‘‘novel’’ genes and the study
of cell cultures in such patients. The patients themselves (two well-
informed young adults) have enthusiastically (and thankfully) given
oral and written informed consent to study their DNA and cells
hoping for results that could help in therapy and/or genetic
counseling.
Case reports
Clinical characterization of a novel type of Ehlers-Danlos
syndrome. We identified a sib pair, a male and a female, with
short stature and a combination of skeletal and connective tissue
findings that could not be classified in existing nosologic categories.
Briefly, these individuals were born at term from uncomplicated
pregnancies. The parents were not knowingly related but
originated from the same region in Portugal; they were healthy
and of average stature. Both sibs were of normal size and weight at
birth but showed progressive short stature beginning in the second
half of the first year of life. Among the clinical signs at that time
were muscular hypotonia and soft skin, leading to the diagnostic
suspicion of the Ehlers-Danlos Syndrome (EDS). During
childhood, the main clinical signs and features were thin, fragile,
but not hyperelastic skin that bruised easily and was particularly
thin on the hands and feet; varicose veins; moderate joint laxity;
blueish or greyish sclerae; downslanting palpebral fissures; and
hypodontia of one or a few teeth in permanent dentition. Both had
astigmatism in childhood. Radiographic examination revealed
moderate osteopenia, flattened or biconcave vertebral bodies with
flaky irregularity of the endplates as well as mild dysplastic changes
at the metaphyses of long bones and of the phalanges. As adults,
the affected male and female subjects were, respectively, 145 and
135 cm tall; their body proportions were normal, indicating that
the platyspondyly was accompanied by shortening of the long
bones. Their skin remained thin and fragile, and the subcutaneous
fat tissue was sparse. Both individuals had marked venous
varicosities on their feet and legs. The male subject suffered
from a cerebral hemorrhage posteriorly to the left putamen at age
21 years, from which he recovered completely. Intellectual
development was above average, and there was no history of
susceptibility to infections. Thus, the patients had features of the
EDS, in particular of EDS type IV (thin and fragile skin, varicose
veins, cerebral hemorrhage) and some signs of osteogenesis
imperfecta (flattened or biconcave vertebrae and grayish sclerae),
but the degree of short stature was unusual, and the facial
appearance with downslanting palpebral fissures as well as the
dysplastic vertebral bodies similarly did not fit either diagnosis well
[29,30,79].
Biochemical characterization of the novel type of Ehlers-
Danlos syndrome. Routine analysis of collagen synthesis in
cultured fibroblasts was normal, ruling out a diagnosis of EDS IV
and making OI unlikely. Analysis of the urinary excretion of
collagen crosslinks revealed that both individuals excreted a
reduced ratio of hydroxylated vs. unhydroxylated collagen
crosslink products in their urine (Supplemental Table S1). The
reduction was statistically significant when compared to that of
either parent, but was milder than that observed in lysyl
hydroxylase deficiency (EDS type VIA)[80,81]. A therapeutic
trial of vitamin C administered orally at a dose of 1 g/day for one
month to stimulate procollagen lysyl hydroxylation in the two
affected individuals did not change the urinary excretion pattern.
After elucidation of the SLC39A13 mutations, Zn levels were
determined twice in both affected individuals in plasma and in
urine to test for a possible perturbation of whole-body Zn
homeostasis; the Zn levels were within the normal range for adults.
This may be consistent with the finding that mouse Slc39a13 is
located in the Golgi and therefore SLC39A13 likely regulates the
intracellular Zn distribution.
Linkage and mutation analysis of the family with the
novel type of Ehlers-Danlos syndrome. Based on the slightly
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but consistently reduced excretion of hydroxylated collagen
crosslink products, we first hypothesized that this condition was
either a variant of EDS VIA or another enzymatic deficiency
leading to impaired procollagen lysyl hydroxylation, but extensive
linkage analysis under a model of recessive inheritance and
targeted mutation analysis excluded the three procollagen lysyl
hydroxylase genes PLOD1, PLOD2, and PLOD3 as responsible for
the disease; further studies excluded the genes, COL1A1, COL1A2,
COL3A1, and CRTAP.
Supporting information
Information for plasmid construction and transfection, skeletal
staining, primary cell culture condition, measurement of maxilla
and mandibles, and analysis of human biological samples was
described in Text S1.
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0003642.s001 (0.00 MB )
Figure S1 Generation of Slc39a13-KO mice. A. Schematic
diagram of the construct used to generate Slc39a13-KO mice. A
targeting vector was constructed with a Neo-cassette inserted into
the region between exons 5 and 9 of Slc39a13 locus. TK:
thymidine kinase B. Infants produced by crosses between
heterozygotes were genotyped by PCR using specific primers (F,
R1 and R2, shown in Figure S1A). WT: wild-type, HE:
heterozygote, KO: Slc39a13-KO. C. Slc39a13 gene expression
in mouse tissues assessed by RT-PCR. sLN: superficial inguinal
lymph node, mLN: mesenteric lymph node, BM: bone marrow
cells, DBM: without bone marrow cells.
Found at: doi:10.1371/journal.pone.0003642.s002 (0.73 MB TIF)
Figure S2 Growth retardation of Slc39a13-KO mice. A. Left:
Little significant difference in skeletogenesis and body size at
newborn between wild-type and Slc39a13-KO mice. Bar indicates
1 cm; Right: Body weight of newborn mice (n = 5 for each). Data
represent mean6S.D. B. Significant delayed growth is observed
after 3 weeks of age (n = 5; male mice). Data represent mean6S.D.
C. Both male and female Slc39a13-KO mice show growth
retardation (n = 10 for each). Data represent mean6S.E.M. WT:
wild-type mice, HE: heterozygote mice, KO: Slc39a13-KO mice.
Found at: doi:10.1371/journal.pone.0003642.s003 (1.41 MB TIF)
Figure S3 Skeletal histomorphometry of Slc39a13-KO mice. A-
D: Bone histomorphometric analysis. Data represent mean6S.D.
A. BMD (bone mineral density) in skull, mandible, cortex, and
cancellous zone of femur are decreased in 5-week-old Slc39a13-
KO mice compared with wild-type mice (n = 5 for each). B. Bone
volume and osteoid thickness of 4-week-old Slc39a13-KO mice
are lower than those of wild-type (n = 5 for each). C. Osteoblast
function is significantly decreased in Slc39a13-KO mice. A
double-labeling analysis of calcein (left), mineral apposition ratio
(middle), and first and second calcein bone formation rate (right) of
4-week-old mice (n = 5 for each). D. Osteoclast activity of
Slc39a13-KO mice is equivalent to wild-type littermates. Eroded
surface (left), osteoclast number (middle), and osteoclast-covered
bone surface (right) of 4-week-old Slc39a13-KO and wild-type
mice are shown (n = 5 for each).
Found at: doi:10.1371/journal.pone.0003642.s004 (0.94 MB TIF)
Figure S4 Abnormal cartilage development in Slc39a13-KO
mice. A. Length of femur (upper) and tibia (lower) of 4-week-old
Slc39a13-KO mice are shorter than those of wild-type (n = 5 for
each). Data represent mean6S.D. B. Genes involved in chondro-
cyte differentiation (left) and in cell adhesion or polarity (right) are
dysregulated in Slc39a13-KO primary chondrocytes. Gene
expression profiling by DNA microarray analysis was carried out
using total RNA from Slc39a13-KO or wild-type primary
chondrocytes. Each gene was normalized to the median of the
measurement for that gene. C. Abnormal morphology of growth
plate in Slc39a13-KO mice. H&E staining images are shown. PZ:
proliferative zone. HZ: hypertrophic zone. Bar indicates 100 mm.
Found at: doi:10.1371/journal.pone.0003642.s005 (4.46 MB
DOC)
Figure S5 Impaired craniofacial skeletogenesis in Slc39a13-KO
mice. A. The following points are traced on the cephalometric
radiographs: Upper; Ba, Basion, defined as the most posterior-
inferior cephalometric maxilla point; Rh, Rhinion, the most
anterior point of the nasal bone; and Na, Nasion, the
cephalometric point between the nasal bone and the frontal bone.
Lower; Me, Menton, the lowest point of the chin; Go, Gonion, the
most posterior inferior point at the angle of the mandible; and Co,
Condylion, the most posterior superior point on the condyle of the
mandible. B-F. Dwarfed craniofacial formation in Slc39a13-KO
mice. Analysis of the 5-week-old maxilla and mandible bone
reveals that Slc39a13-KO mice are characterized by shorter
craniofacial depth (B. Ba-Rh), shorter nasomaxillary depth (C. Na-
Rh), shorter cranial base depth (D. Na-Ba), shorter mandibular
depth (E. Me-Go), and shorter craniofacial depth (F. Me-Co),
compared with wild-type mice (n = 5 for each). Data represent
mean6S.D.
Found at: doi:10.1371/journal.pone.0003642.s006 (0.75 MB TIF)
Figure S6 Perturbation of BMP/TGF-b signal transduction
without affecting phosphorylation of Smad proteins in Slc39a13-
KO cells. A. DNA microarray analysis using RNA of primary
osteoblasts (left) and chondrocytes (right). Each gene was
normalized to the median of the measurement for that gene. B.
Smad proteins are normally phosphorylated in Slc39a13-KO cells.
Primary osteoblasts or dermal fibroblasts were stimulated with
either 50 ng/ml of BMP4 (left), or 10 ng/ml of TGF-b1 (right),
respectively for indicated periods. Total cell lysates were separated
by SDS-PAGE, followed by immunoblotting with either anti-
phosphorylated Smad1/5/8 (pSmads), anti-Smad1, anti-phos-
phorylated Smad2 (pSmad2), anti-Smad2/3, or anti-Scl39a13
specific antibodies. Anti- a -tubulin antibody was used for control
blotting.
Found at: doi:10.1371/journal.pone.0003642.s007 (0.84 MB TIF)
Figure S7 Dysregulated expression of tibial Msx2 and Rnux2 in
Slc39a13-KO mouse. ISH analysis shows Runx2 is accumulated
(right), while Msx2 is diminished (left) in 4-week-old Slc39a13-KO
tibia. Regions indicated as 1 and 2 in upper are enlarged as 200
times at middle and lower panels.
Found at: doi:10.1371/journal.pone.0003642.s008 (8.41 MB TIF)
Figure S8 Dysregulated expression of molar Msx2 and dermal
type 1 collagen expression in Slc39a13-KO mouse. A. ISH
analysis shows Msx2 gene expression is diminished in odontoblasts
(od) lining the dentin of crown (w) of 10-day-old Slc39a13-KO
molar teeth. Regions indicated with w in upper are enlarged as
200 times at lower panels. Unorganized odontoblasts are observed
in Slc39a13-KO molar. B. Type I collagen level is decreased in
Slc39a13-KO skin. Skin section of 5-week-old wild-type and
Slc39a13-KO mice were applied for IHC. Bar indicates 100 mm.
Found at: doi:10.1371/journal.pone.0003642.s009 (5.71 MB TIF)
Figure S9 Involvement of Slc39a13 in localization of Smad
proteins. A and B. Slc39a13 is involved in BMP/TGF-b -induced
nuclear localization of phosphorylated Smad proteins. Primary
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osteoblasts (A) or dermal fibroblasts (B) were stimulated with either
50 ng/ml of BMP4 for 15 minutes (A, right panels) or 10 ng/ml of
TGF-b1 for 30 minutes (B, right panels), respectively, followed by
staining for phosphorylated Smad1/5/8 (pSmads), phosphorylated
Smad2 (pSmad2), nuclei (DAPI), and actin (Actin). Confocal
microscopic images are shown. C and D. Ratio of subcellular
localization of intact (C) or phosphorylated (D) Smad proteins was
obtained by counting cells (n = 50) in confocal microscopy images
visualized by anti- Smad1, anti-Smad2/3, anti-phosphorylated
Smad1/5/8 (pSmad), or anti- phosphorylated Smad2 (pSmad2)
antibodies after BMP4 (left in C and D; for Smad1 and pSmads in
osteoblasts) or TGF-b1 (right in C and D; for Smad2/3 and
pSmad2 in dermal fibroblasts) stimulation. nuc: nuclear space,
cyto: cytoplasmic space, both: both of nuclear and cytoplasmic
spaces E and F. Cytoplasmic and nuclear fractions from primary
osteoblasts (E) and dermal fibroblasts (F) were separated by SDS-
PAGE, followed by immunoblotting with either anti-phosphory-
lated Smad1/5/8 (pSmads) and anti-Smad1 (E), or anti-phos-
phorylated Smad2 (pSmad2) and anti-Smad2/3 (F) antibodies.
Anti- a-tubulin and HDAC1 antibodies were used for control
blotting.
Found at: doi:10.1371/journal.pone.0003642.s010 (2.36 MB TIF)
Figure S10 Ectopic expression of Slc39a13. Either empty vector
(mock), Flag-tagged wild-type (WT), or G74D mutated (G74D)
mouse Slc39a13 expression plasmids were transfected into
Slc39a13-KO primary osteoblasts (A) and dermal fibroblasts (B).
Their expression level was assessed by RT-PCR (upper), and by
immunoblotting using anti-Flag and anti-a-tubulin antibodies at
two days after transfection (lower).
Found at: doi:10.1371/journal.pone.0003642.s011 (0.72 MB TIF)
Table S1 Molar ratio of hydroxylysyl/lysyl-pyridinoline collagen
crosslinks in urine of the two sibs with EDS and in their parents.
Found at: doi:10.1371/journal.pone.0003642.s012 (0.71 MB TIF)
Table S2 Primer sequences used for RT-PCR are listed.
Found at: doi:10.1371/journal.pone.0003642.s013 (0.97 MB TIF)
Table S3 Primer sequences used for real time-PCR are listed.
Found at: doi:10.1371/journal.pone.0003642.s014 (0.77 MB TIF)
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